Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Soroka Medical Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : SCI-110 is a unique and proprietary combination of Dronabinol, an FDA-Approved, synthetic version of delta-9-tetrahydrocannabinol, and CannAmide™, the Company's proprietary formulation of Palmitoylethanolamide (PEA).
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Soroka Medical Center
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SCI-210
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Negev Autism Center, Soroka University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 10, 2022
Lead Product(s) : SCI-210
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Negev Autism Center, Soroka University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Collaboration
Neuraxpharm Enters the Advanced Medical Cannabis Market in Germany with A Collaboration with Panaxia
Details : The establishment of the business collaboration reflects Neuraxpharm’s and Panaxia’s strategy to become a European leader in the commercialization of medical cannabis products.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 04, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vaginal Postpartum Pain Management Protocol Comparison
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2019
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fremanezumab Compassionate Use Program for Pediatric Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 29, 2018
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Israel Science Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 08, 2017
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Israel Science Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shifting Pain Modulation From Pro-to Anti-nociceptive
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2016
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amitriptyline
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Migraine Research Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Prediction of Migraine Prevention Efficacy Based on Individual's Pain Modulation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 02, 2014
Lead Product(s) : Amitriptyline
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Migraine Research Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison Between Two Analgesic Methods for Pain Relief Following Surgical Abortion
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 31, 2013
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 24, 2013
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable